RU2415137C2 - Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе - Google Patents

Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе Download PDF

Info

Publication number
RU2415137C2
RU2415137C2 RU2008131906/04A RU2008131906A RU2415137C2 RU 2415137 C2 RU2415137 C2 RU 2415137C2 RU 2008131906/04 A RU2008131906/04 A RU 2008131906/04A RU 2008131906 A RU2008131906 A RU 2008131906A RU 2415137 C2 RU2415137 C2 RU 2415137C2
Authority
RU
Russia
Prior art keywords
disease
dementia
indole
hydroxy
salt
Prior art date
Application number
RU2008131906/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008131906A (ru
Inventor
Анна-Лена БЕРГ (SE)
Анна-Лена Берг
Рэтан БХЭТ (SE)
Рэтан БХЭТ
Тесфаи СЕБХАТУ (SE)
Тесфаи СЕБХАТУ
Эрика СТОХЛЕ (SE)
Эрика СТОХЛЕ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2008131906A publication Critical patent/RU2008131906A/ru
Application granted granted Critical
Publication of RU2415137C2 publication Critical patent/RU2415137C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2008131906/04A 2006-02-02 2007-01-31 Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе RU2415137C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76455106P 2006-02-02 2006-02-02
US60/764,551 2006-02-02

Publications (2)

Publication Number Publication Date
RU2008131906A RU2008131906A (ru) 2010-03-10
RU2415137C2 true RU2415137C2 (ru) 2011-03-27

Family

ID=38327680

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008131906/04A RU2415137C2 (ru) 2006-02-02 2007-01-31 Цитратная соль производного индола, способ ее получения, ее применение и фармацевтическая композиция на ее основе

Country Status (24)

Country Link
US (2) US8008294B2 (enExample)
EP (1) EP1981869A4 (enExample)
JP (1) JP2009525324A (enExample)
KR (1) KR20080098022A (enExample)
CN (2) CN101378754A (enExample)
AR (1) AR059225A1 (enExample)
AU (1) AU2007210336B2 (enExample)
BR (1) BRPI0706745A2 (enExample)
CA (1) CA2641900A1 (enExample)
EC (1) ECSP088647A (enExample)
IL (1) IL192888A0 (enExample)
MX (1) MX2008009719A (enExample)
MY (1) MY146102A (enExample)
NO (1) NO20083784L (enExample)
NZ (1) NZ570849A (enExample)
PE (1) PE20090192A1 (enExample)
RU (1) RU2415137C2 (enExample)
SA (1) SA07280004B1 (enExample)
SG (1) SG169381A1 (enExample)
TW (1) TW200800977A (enExample)
UA (1) UA94251C2 (enExample)
UY (1) UY30126A1 (enExample)
WO (1) WO2007089191A1 (enExample)
ZA (1) ZA200806725B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
CN101679353A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 制备化合物2-羟基-3-[5-(吗啉-4-基甲基)吡啶-2-基]1h-吲哚-5-腈701的新方法
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN120441567A (zh) * 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082853A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab New compounds
WO2005027823A2 (en) * 2003-09-24 2005-03-31 Astrazeneca Ab 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1373263T1 (en) 2001-04-05 2005-04-30 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003009588A (ja) 2001-06-20 2003-01-10 Toshiba Corp 車両連続運転装置用インバータ装置
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
SA07280004B1 (ar) * 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082853A1 (en) * 2002-03-28 2003-10-09 Astrazeneca Ab New compounds
RU2004125146A (ru) * 2002-03-28 2005-06-27 Астразенека Аб (Se) Новые соединения
WO2005027823A2 (en) * 2003-09-24 2005-03-31 Astrazeneca Ab 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)

Also Published As

Publication number Publication date
ZA200806725B (en) 2009-07-29
CN101379053A (zh) 2009-03-04
EP1981869A4 (en) 2010-08-25
NO20083784L (no) 2008-10-13
NZ570849A (en) 2011-01-28
UA94251C2 (ru) 2011-04-26
CA2641900A1 (en) 2007-08-09
AU2007210336B2 (en) 2011-03-24
MY146102A (en) 2012-06-29
JP2009525324A (ja) 2009-07-09
AU2007210336A1 (en) 2007-08-09
TW200800977A (en) 2008-01-01
BRPI0706745A2 (pt) 2011-04-05
SG169381A1 (en) 2011-03-30
ECSP088647A (es) 2008-08-29
PE20090192A1 (es) 2009-03-20
US20090023732A1 (en) 2009-01-22
UY30126A1 (es) 2007-09-28
EP1981869A1 (en) 2008-10-22
KR20080098022A (ko) 2008-11-06
RU2008131906A (ru) 2010-03-10
AR059225A1 (es) 2008-03-19
US8008294B2 (en) 2011-08-30
MX2008009719A (es) 2008-09-04
WO2007089191A1 (en) 2007-08-09
US20070203137A1 (en) 2007-08-30
SA07280004B1 (ar) 2011-10-29
IL192888A0 (en) 2009-02-11
CN101378754A (zh) 2009-03-04

Similar Documents

Publication Publication Date Title
EP1575938B1 (en) Compounds having selective inhibiting effect at gsk3
WO2007120102A1 (en) New substituted oxindole derivatives
JP2010535200A (ja) ２−ヒドロキシ−３−［５−（モルホリン−４−イルメチル）ピリジン−２−イル］−１ｈ−インドール−５−カルボニトリル・クエン酸塩の新しい結晶形態
EP1458395B1 (en) Medical use of gsk3-inhibiting oxindole derivatives
US10160746B2 (en) 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US20120101132A1 (en) New Substituted Oxindole Derivative
US8008294B2 (en) Citrate salt of an indole derivative and its pharmaceutical use
US20100256133A1 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
US20110028489A1 (en) Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders
US20090018130A1 (en) Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid
US20120115865A1 (en) New Salts of an Indole Derivative and Their Use in Medicine
CN112055590A (zh) 用于治疗醛固酮增多症的r-法屈唑
HK1129382A (en) New citrate salt of an indole derivative and its pharmaceutical use
WO2012050517A1 (en) Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
WO2024059659A1 (en) Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
WO2024059661A1 (en) N-(benzhydryl)cycloalkylcarboxamide derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
HK1080856B (en) Compounds having selective inhibiting effect at gsk3
HK1142070A (en) Compounds having selective inhibiting effect at gsk3
HK1203930B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130201